NCT02269813View on ClinicalTrials.gov

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

CompletedOBSERVATIONAL
Enrollment

452

Participants

Timeline

Start Date

April 1, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

September 30, 2016

Conditions
Breast Cancer
Interventions
OTHER

MammaPrint

OTHER

BluePrint

OTHER

TargetPrint

Trial Locations (3)

6020

Medizinische Universität Innsbruck Universitätsklinik für Frauenheilkunde, Innsbruck

9007

Kantonsspital St.Gallen, Sankt Gallen

81377

Breast Center of the University of Munich (LMU), Munich

Sponsors

Collaborators (1)

Agendia
All Listed Sponsors
collaborator

Agendia

INDUSTRY

lead

West German Study Group

OTHER

NCT02269813 - PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe) | Biotech Hunter | Biotech Hunter